Frontiers in Pharmacology manuscript!


In collaboration with Hapuarachchige group (JHU, Baltimore, US) we used the trans-cyclooctene click chemistry to functionalize our 5D3 mAb targeting prostate-specific membrane antigen (PSMA) with an Aurora A kinase inhibitor MLN8237. The resulting ADC showed high potency an selectivity in controlling the growth of PSMA-positive tumors in preclinical animal models of prostate cancer with minimal side effects. Congratulation to all co-authors on this interesting story!